On Thursday, Shares of Baxalta Incorporated (NYSE:BXLT), surged 7.54% to $33.37.
Baxalta Incorporated, declared that Health Canada has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in patients with attained hemophilia A caused by autoantibodies to coagulation Factor VIII (FVIII), a very rare and life-threatening acute bleeding disorder. OBIZUR is the first recombinant porcine sequence FVIII treatment available for patients with attained hemophilia A, specifically designed to enable physicians to monitor treatment response by measuring FVIII activity levels in addition to clinical assessments.
The approval is supported by the positive results of a global, prospective, controlled, multi-center Phase II/III open-label clinical trial that examined the efficacy of OBIZUR in the treatment of serious bleeding episodes in patients with attained hemophilia A. All patients treated with OBIZUR, 100 percent (28/28), showed a positive response and clinical improvement at 24 hours after the initial infusion. Successful control (resolution) of the initial bleeding episode was observed in 86 percent (24/28) of all patients and in 94 percent (16/17) of those treated with OBIZUR as the first-line treatment. The development of antibodies to porcine FVIII was the only adverse reaction stated in more than five percent of patients.
OBIZUR is now approved in the United States and Canada, and is under regulatory review in the European Union, Switzerland, Australia and Colombia.
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.
On other hand, Shares of MannKind Corp., saw its price movement on above normal volume, as 5.71M shares changed hands when compared with its average daily volume of 4.29M shares. The stock was up 4.10% to $3.05. The stock, as of recent close, has shown weekly downbeat performance of -7.01% which was maintained at -42.99% in this year. At the end of recent trade, the stock has moved down across its SMA 200 of $4.56.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
